MedTrace Logo

The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy

NCT01897077 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-07-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if a new method of administration of peanut sublingual immunotherapy, a dissolving peanut film, is effective.

Conditions

Interventions

DRUG

Peanut Dissolving Film

Sponsors & Collaborators

Principal Investigators

  • Robert Wood, MD · Johns Hopkins University

  • Corinne Keet, MD, MS · Johns Hopkins University

  • Hugh Sampson, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-02-03
Completion
2013-02-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01897077 on ClinicalTrials.gov